Although some of the basics of mtDNA replication and transcription are known, much is either controversial or remains to be discovered 5, [10] [11] [12] . Abnormalities of mtDNA replication and transcription (such as production of deleted species) or translation (due to mutations in tRNA or coding ETC genes) are responsible for illnesses present in childhood or early adulthood involving high energy, post-mitotic tissues such as brain, retina, heart and skeletal muscle 1, 2 . These "mitochondrial" diseases can display variable and overlapping phenotypes, and understanding their genotype-phenotype relationships remains a great challenge 1, 2 .
Further insights into understanding mitochondrial genome replication and expression, in addition to development of novel therapies for mitochondrial diseases, a G11778A mtDNA mutation in the ND4 gene from a patient afflicted with Leber's Hereditary Optic Neuropathy (LHON), a cause of retinal ganglion cell degeneration and blindness in young adults 18, 19 . Incubation with Alexa488-labeled MTD-TFAM revealed rapid entry of MTD-TFAM into the mitochondrial compartment ( Figure 1C ).
We next investigated if MTD-TFAM could alter the mitochondrial physiology in these LHON cybrid cells. Three consecutive independent experiments were carried out over several months in which LHON cybrid cells at the same initial passage numbers were treated with MTD-TFAM or buffer control (CTL). The two groups of cells in each of the three independent experiments were passed in parallel to generate adequate cell densities to carry out multiple, simultaneous "high-resolution" oximetry-respiration experiments using intact cells metabolizing glucose 20 . In this approach, basal, ETC complex-dependent and incrementally uncoupled respiration rates were assayed in real time where all metabolic control systems were otherwise intact. Nine million living cells from individual experiments and their CTL were added to each 2 ml. respiration chamber. The basal respiration values were depicted as a function of the same number of live cells expressed as a percentage of the corresponding buffer control cell values at each of the time point. We observed that exposure to MTD-TFAM caused a time-dependent, reversible increase in basal respiration rates that reached a maximal ~3-fold increase over control samples at around 2 weeks (Figure 2A ). Our second and third respiration experiments were designed to reproduce the apparent peak effect at ~2 weeks and then explore additional respiration responses before and after the time of apparent peak effect.
We observed that peak respiration responses occurred between ~2-2.5 weeks after MTD-TFAM exposure and returned to CTL values over the next week.
Because TFAM is a recognized essential factor for mitochondrial genome replication and transcription, one possible explanation for this result is that MTD-TFAM exposure was increasing mitochondrial gene replication, transcription and translation into respiratory proteins. We used multiplex qPCR for several mitochondrial genes to monitor alterations in mitochondrial gene copy numbers in genomic DNA samples or mitochondrial gene expression in cDNA samples. We show averaged values for three mitochondrial genes (ND2, ND4, CO3) whose copy numbers were normalized to that of nuclear DNA-encoded 18S rRNA in the genomic DNA or total RNA (cDNA) samples In the third experimental series of LHON cybrid cell samples exposed to MTD-TFAM, we examined the levels of multiple individual ETC proteins with Western blots.
We also studied assembly of ETC macrocomplexes with immunohistochemistry using antibodies directed against mtDNA-encoded catalytic subunits of complexes I and IV, We then treated normal adult male mice with I.P. injections of MTD-TFAM or buffer control and assayed respiration in mitochondrial preparations from brain, heart, and liver. Mice injected twice, 48 hrs apart, with MTD-TFAM sufficient to bind ~100 ug of DNA in each injection showed increased respiration one week later. The greatest relative increase (compared to buffer control) was observed for respiration with complex I substrates (glutamate/malate) in heart mitochondria ( Figure 3A ). Respiration through several ETC complexes showed small increases for brain, heart and liver. In our mitochondrial preparations we observed substantial differences across tissues in the relative State 3 (+ADP) respiration rates for individual complexes ( Figure 3B ). Heart mitochondria showed the smallest relative proportion of complex I-mediated respiration, but also had the greatest relative increase in complex I-mediated respiration after MTD-TFAM treatment. It is not yet known whether these respiration changes derive from alterations in expression of mitochondrial ETC genes, mitochondrial mass, or some combination.
In this study, we have shown that the naturally occurring TFAM protein which is essential for mtDNA expression and replication can be engineered with a protein transduction domain and mitochondrial localization signal (MTD-TFAM) so as to be able to enter rapidly into the mitochondrial compartment of cells. After developing a scalable production procedure, we found that incubation for only a few hours with MTD-TFAM, These initial observations demonstrate that MTD-TFAM can be produced in high purity in a scalable manner in quantities sufficient for in vivo studies, and that MTD-TFAM reversibly alters mitochondrial respiratory physiology. Much remains to be characterized about the mechanisms underlying our observations, and the therapeutic potential of MTD-TFAM for treating diseases associated with bioenergetic deficiency is worthy of further investigation. More importantly, our findings show that the mitochondrial genome is no longer an isolated site and can be manipulated from outside the cell with protein transduction technology.
Methods

Expression of MTD-TFAM
The nucleotide sequence corresponding to PTD-MLS-Tfam i was subcloned into PE-
Sumo3 (Life Sensors). The construct was transformed into Tuner (DE3)pLysS cells (Novagen). Recombinant protein was expressed by the transformed bacteria cultured in
Overnight Express TB medium (Novagen), an auto-induction media, supplemented with 100 µg/ml ampicillin and 30 µg/ml chloramphenicol in a Bioflo 310
Fermentor/Bioreactor (New Brunswick). Growth and expression of the bacteria culture were performed at 37º C, dissolved oxygen 30%, with variable agitation and airflow.
When culture achieved an optical density of 25 the bacteria were harvested and pelleted by centrifugation at 3500 g and stored at -80 degrees. glucose were added to each chamber of an Oroboros Oxygraph 2 respirometer and studied intact with "high resolution respirometry". After assay of basal respiration rates, ATP synthase was inhibited with oligomycin and mitochondria were incrementally uncoupled with FCCP injection to estimate maximal uncoupled respiration that was sequentially inhibited with rotenone to inhibit complex I followed by antimycin A/myxothiazole to inhibit complex III.
RT-qPCR analysis of mitochondrial gene expression
Total genomic DNA and total RNA were isolated from cell pellets using All-Prep kits from Qiagen and amounts assayed with Quant-IT DNA and RNA assays (InVitrogen). 1 ug of total RNA was reverse transcribed into cDNA using iScript (BioRad). Levels of 18S rRNA were assayed using SybrGreen detection (BioRad) in genomic DNA or cDNA samples and Roche human genomic DNA as standard. Copy numbers of 12S rRNA, ND2, CO3 and ND4 mitochondrial genes were assayed in a multiplex qPCR assay (BioRad Powermix) using a full-length PCR product of human mtDNA as standard. All RT-qPCR was carried out in an iQ5 thermocycler (BioRad) using primers and probes designed with Beacon Designer software. Levels of mitochondrial genes were normalized to 18S rRNA in either DNA or RNA (cDNA) samples.
SfaN1 restriction analysis
A PCR product in the ND4 gene spanning the SfaN1 site removed by the G11778A mutation was amplified from genomic DNA or cDNA and digested with SfaN1.
Digestion products were analyzed using automated electrophoresis (Experion, BioRad).
Western blot analysis of ETC proteins 100 ug of total cell protein were loaded onto 4-12% Bis-Tris CriterionTM precast gels (BioRad) and separated. The proteins were then transferred to nitrocellulose membranes using the iBlot transfer system (Invitrogen). Complex I subunits were detected by immunoblotting using the following antibodies purchased from Mitosciences: MS111 against subunit NDUFA9 at 1.125 µg/mL, MS110 against subunit NDUFS3 at 0.5 µg/mL, MS109 against an 8kDa subunit at 1 µg/mL, MS107 against subunit NDUFB4 at 0.5 µg/mL, and MS105 against subunit NDUFB8 followed by an IRDye® 800 goat antimouse secondary at 1:15,000 (Li-cor). Subunits from complexes I-V were detected by immunoblotting using the Mitoprofile® human total OXPHOS complexes detection kit at 1:575 (Mitosciences) followed by an IRDye® 800 goat anti-mouse secondary at 1:25,000
(Li-cor). Mitofilin was assayed as an estimate of mitochondrial mass in each sample and was detected by immunoblotting using the MSM02 antibody at 2 µg/mL purchased from
Mitosciences followed by an IRDye® 800 goat anti-mouse secondary (Li-cor). Betaactin was used as a loading control and was detected by immunoblotting using a polyclonal beta-actin antibody purchased from Abcam followed by an IRDye® 680 goat anti-rabbit secondary at 1:15,000 (Li-cor). The membranes were visualized and bands quantiated using the Odyssey infrared imaging system (Li-cor).
Immunohistochemical analysis of ETC macrocomplex assembly
Cells were grown to subconfluence (70-80%) in polylysine coated Mattek dishes, fixed with 4% parafomaldehyde in 0.1M PBS for 20min., rinsed in PBS and stained following the protocol recommended by Mitosciences (www.mitosciences.com) Briefly, fixed cells were treated with antigen retrieval buffer (5% urea in 100mM Tris, pH 9.5) at 95°C for 20 min, followed by 3 washes with PBS, 0.2% Triton-X-100 in PBS for 15 min and 3 more washes with PBS. Cells were blocked in 10% goat serum for one hour at room temp.; primary antibodies (Mitosciences) were added to each dish in 10% goat serum:
anti-complex 1 (MS602-1 NDUFB4) 50μg/ml; anti-complex 4, subunit 1 (MS602-IV)
6.25μg/ml; anti-complex 5α control (MS602-CVα) 1.25μg/ml and incubated at 4°C
overnight. Cells were washed in 1% goat serum; secondary antibodies were added to each as recommended by the protocol and incubated at room temperature for 2 hours. On day 7 mice were sacrificed and organs from MTD-TFAM or buffer CTL injected mice were processed in equal weights in parallel to make P2 pellets, which were studied for substrate-specific State 3 (+ADP) respiration. (a) Shown are averaged (n=3 pairs) respiration rates for MTD-TFAM injected mice for brain,
